ReviewWorld journal of oncology2021

Checkpoint Inhibitors in Relapsed/Refractory Classical Hodgkin Lymphoma.

Kidist Tarekegn et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.